1. Screening and Prevention Research
2. Biomarker Discovery and Assay Development
3. Anti-Cancer Therapeutics

With plenty of opportunity  for networking and debate, this informal international  meeting will bring you up to date with current research and thinking regarding cancer screening, prevention and treatment.

Who Should Attend
The conference is open to academics, clinicians and industrial partners creating a stimulating environment in which to promote lively discussion, productive collaboration and innovation. 

Program Outline

Day 1:  Advances in Cancer Screening and Prevention Research 
This session will discuss current research and clinical trials for the prevention of cancer, focusing on screening, early detection and chemoprevention.

Day 2;  Cancer Biomarker Discovery and Assay Development
Whilst numerous challenges exist in translating biomarker research into the clinical space; a number of gene and protein based biomarkers are already being used at some point in patient care. This session will discuss the further discovery and assay development of genetic, epigenetic, proteomic, glycomic, and imaging biomarkers which can be used for cancer diagnosis, prognosis, and epidemiology.  We provide an informal atmosphere for discussion and debate.

Day 3:  Anti-Cancer Therapeutics: From research to trials to treatment 
This session will discuss development of therapies for cancer treatment including, but not exclusively biologicals, looking at discoveries in the laboratory to clinical phase trials.  This is not only an ideal place to showcase research and development but also to discover what may become new on the market and to network with experts in the field. In addition, this session will highlight ground-breaking developments in cancer therapeutics providing a unique opportunity to listen and contribute to discussions on a variety of topics  including small molecule and antibody based drugs, genetic studies, gene therapy and clinical trials

This is an ideal setting for experts to present their work and discuss their findings

Talks include

The selective targeting of cell survival pathways in cancer cells
Dr. Mark Guthridge, Senior Research Fellow, Australian Centre for Blood Diseases, Monash University, Melbourne, Australia

Translating antibodies engineered with IgE Fc regions to elicit enhanced effector functions for cancer therapy
Dr. Sophia N. Karagiannis, Senior Research Fellow in Translational Cancer Immunology, Head of Cancer Antibody Discovery and Immunotherapy, St. John’s Institute of Dermatology, Division of Genetics and Molecular Medicine, King’s College London School of Medicine, UK

The European Prostate cancer screening trial  ERSPC: outcomes and methods for risk stratification.
Dr Monique Roobol, Associate professor, epidemiologist, Erasmus University Medical center, Rotterdam, The Netherlands

Estonian experience in establishing a cancer screening registry: opportunities and challenges of the e-healthera
Dr Piret Veerus, Senior researcher, National Institute for Health Development, Estonia

Targeting leukemic stem cells to improve treatment of  chronic myeloid leukemia.
Dr. Xiaoyan Jiang, Senior Scientist and Associate Professor, Terry Fox Laboratory,  BC Cancer Agency Medical Genetics, University of British Columbia, Canada

Head and Neck Cancer (HNC) Screening in National and High-risk Populations in Ireland
Dr Eleanor O’Sullivan, Clinical Lecturer, Cork University Dental School & Hospital, Ireland

Quality Control in Cervical Cancer Screening
Dr Alenka Repše Fokter, MD, Ph.D, MIAC, cytopathologist, Dept. of Pathology and Cytology, Celje general Hospital, Slovenia

Towards implementation of lung cancer screening: refining methods to maximise effectiveness
Professor David Baldwin, Consultant Physician, Nottingham University Hospitals, UK

Mammography Screening for Breast Cancer.  Is it living up to its promise
Dr Anthony Miller, Professor Emeritus, Dalla Lana School of Public Health, University of Toronto, Canada

Translating antibodies engineered with IgE Fc regions to elicit enhanced effector functions for cancer therapy
Dr. Sophia N. Karagiannis, Senior Research Fellow in Translational Cancer Immunology, Head of Cancer Antibody Discovery and Immunotherapy, St. John’s Institute of Dermatology, Division of Genetics and Molecular Medicine, King’s College London School of Medicine, UK

Mesenchymal and rare colorectal carcinomas as a paradigm to identify new biomarkers/alterations of tumor aggressiveness. New pathways, and an  unexpected role of chromatin remodeling complexes
Dr Massimo Pancione, PhD Department of Sciences and Technologies, University of Sannio, Italy

Paediatric lymphoma: diagnosis, biomonitoring and therapy 
Dr Suzanne Turner, Leukaemia and Lymphoma Research Lecturer, Department of Pathology, University of Cambridge, UK

A New Era in the Control of Breast Cancer
Dr Laslzo Tabar, Professor emeritus, Department of Mammography, Falun Central Hospital, Falun, Sweden

Nucleosomics® – A novel epigenetic biomarker discovery platform
Dr Mark Eccleston, Collaborations Manager,  VolitionRx, UK

FKBPL and peptide derivatives and their dual anti-angiogenic and anti-cancer stem cell activity 
Professor Tracy Robson,  Professor of Experimental Therapeutics,  Queen’s University Belfast, Northern Ireland
 
Additional Speakers include

• Professor Vessela Kristensen, University of Oslo, Norway.
• Dr Hendrik-Tobias Arkenau, Medical Oncologist, Sarah Cannon Research Institute UK/University College London, UK